Frontage China Becomes First Certified Service Provider in Asia Pacific & Greater China for Alamar Biosciences, Strengthening Global Biomarker Detection Capabilities
EXTON, Pa., July 21, 2026 –
Frontage China has officially been granted the Certified Service Provider (CSP) designation by Alamar Biosciences, becoming the first laboratory in the Asia-Pacific region and Greater China to receive this official accreditation. The certification integrates Frontage into Alamar Biosciences’ global network of authorized service providers. Leveraging the ARGO™ HT System and the NULISA™ ultra-sensitive protein detection platform, Frontage will deliver high-quality, high-sensitivity protein biomarker testing services in strict accordance with Alamar’s official standards, further enhancing its bioanalytical and translational medicine capabilities.
The Alamar Biosciences Certified Service Provider (CSP) program is an official accreditation framework that recognizes laboratories possessing the technical expertise, quality systems, and operational capacity to perform NULISA™ platform testing to Alamar’s specifications. Previously, the official CSP network was primarily concentrated in Europe and the Americas. Frontage China’s attainment of CSP status not only fills a critical gap in the Asia-Pacific and Greater China regions but also provides regional biopharmaceutical innovators with more accessible, efficient, and internationally compliant testing solutions for drug development.
With this achievement, both Frontage US and Frontage China now hold Alamar Biosciences CSP credentials. Operating under Frontage’s “One World, One System” global unified quality framework, clients can access official-certified testing services that adhere to consistent standards across both China and the U.S., tailored to project requirements. This enables the generation of high-quality, comparable data to support global multi-center clinical trials and cross-regional drug development programs, while ensuring seamless project execution and data consistency across regions.
Earning the Alamar Biosciences CSP designation marks a significant milestone in Frontage’s ongoing commitment to expanding its global bioanalytical capabilities and underscores its international competitiveness in high-sensitivity protein biomarker detection. As a core pillar of Frontage’s business, the bioanalytical platform has evolved over 25 years into a globally integrated network spanning the U.S., China, and Europe, offering comprehensive analytical solutions for small molecules, large molecules, biomarkers, and cell and gene therapy (CGT) products, all while meeting stringent international regulatory requirements.
Powered by cutting-edge technology platforms, extensive project experience, and a
globally harmonized quality management system, Frontage has become a trusted, long-term partner for numerous innovative drug developers and top 30 multinational pharmaceutical companies worldwide. Looking ahead, Frontage will continue to introduce advanced international technologies, broaden the frontiers of its bioanalytical capabilities, and elevate its global service offerings to provide clients with more comprehensive, efficient, and internationally aligned integrated R&D support.
“Alamar Biosciences welcomes Frontage China to our global Certified Service Provider network,” said a spokesperson from Alamar. “With Frontage’s robust quality systems, expert technical teams, and extensive bioanalytical track record, this certification will significantly improve access to NULISA™ platform testing services for clients in the Asia-Pacific region, delivering more efficient and reliable technical support for global innovative drug development.”
About Frontage
Frontage Laboratories, Inc. is a US-based global Contract Research, Development, and Manufacturing Organization (CRO/CDMO) offering fully integrated, science-driven solutions across the drug development journey. Founded in 2001 and headquartered in Pennsylvania, with 28 facilities across the U.S., Canada, Europe and China, Frontage provides seamless end-to-end capabilities – from drug discovery, API synthesis, DMPK, and safety & toxicology to formulation development and manufacturing, CMC analytical, clinical trials, bioanalytical and central lab services. With deep scientific expertise and strong operational execution, Frontage supports innovative, generic, and consumer health companies of all sizes in achieving IND, NDA, ANDA, BLA, and 505(b)(2) submissions – helping turn bold ideas into real-world therapies.
SOURCE Frontage Laboratories, Inc.